Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T-Reference-Cited by-同舟云学术

Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T

Published:2021-03-24 Issue:4 Volume:10 Page:362-376
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Singh Aman P.¹,Chen Wenbo¹,Zheng Xirong¹,Mody Hardik¹,Carpenter Thomas J.¹,Zong Alice¹,Heald Donald L.¹

Affiliation:

1. Discovery and Translational Research Biologics Development Sciences Janssen Biotherapeutics Spring House Pennsylvania USA

Funder

Johnson and Johnson

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12598

Reference50 articles.

1. Programming CAR-T cells to kill cancer

2. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

3. U.S. FDA approves Kite’s Tecartus™ the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma.Gilead Sciences 2020.

4. Beacon Targeted Therapies Database.https://data.beacon‐intelligence.com/(2020).

5. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges;Signal Transduction and Targeted Therapy;2024-09-13

2. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment;eBioMedicine;2024-08

3. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors;Journal for ImmunoTherapy of Cancer;2024-07

4. DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges;Drug Metabolism and Pharmacokinetics;2024-06

5. Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics;npj Systems Biology and Applications;2024-03-18